Jupiter, F.L., June 11, 2026 (GLOBE NEWSWIRE) — Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has closed a $5.13 million seed financing to advance development of its exosome-based therapeutics and diagnostics platform focused on longevity and regenerative medicine.
This raise underscores the growing support and shareholder’s backing of Human Continuum’s mission to advance next-generation biologic solutions in addressing a variety of health issues through innovation in exosome therapies.
Figure 1 – Human Continuum Inc. Closes Over $5 Million Seed Funding Round.
The prevalence of ailments such as musculoskeletal diseases such as osteoarthritis, which affect more than 60 million adults in the United States alone, reinforces the need for cutting-edge therapies and treatments. HC’s exosome platform seeks to harness the regenerative signals released by platelets, without the cells themselves, offering a minimally invasive, scalable, and standardized approach for regenerative medicine. In parallel, its development of topical exosome dermatologic formulations, point-of-care exosome diagnostic technology and an exosomal biomarker panel for longitudinal monitoring of orthopedic diseases, produce a comprehensive platform to support human health and longevity.
Figure 2 – Dr. Sean Law, MD, MBA, Chief Executive Office (left) alongside Dr. Omar K. Sial, Ph.D., Chief Scientific Officer (right) of Human Continuum.
“Human Continuum reflects not only our identity as a company but the foundation of our mission: advancing long-term health and longevity,” said Dr. Sean Law, MD, MBA, Chief Executive Officer and Board Member of Human Continuum. “The support our shareholders have demonstrated through this raise is critical to that mission and the work ahead of us. The capital will allow us to move forward on several key fronts, including expanding our technical team and strengthening our research and development capabilities. We are focused on ensuring HC is well positioned to contribute meaningfully to this exciting sector.”
“This raise represents a meaningful step forward for the Company and will allow us to accelerate the development of a fully integrated exosome-based therapeutics platform,” said Dr. Omar K. Sial, Ph.D., Chief Scientific Officer of Human Continuum. “The timing is significant, as we are making tangible progress across several key development pipelines. We are grateful for the continued confidence our shareholders have placed in the Company and in the scientific excellence underpinning our team’s work.”
Figure 3 – Dr. Sean Law, MD, MBA, Chief Executive Office (near) alongside Dr. Omar K. Sial, Ph.D., Chief Scientific Officer (far) of Human Continuum.